Conference Reports for NATAP

Back

AASLD The Liver Meeting November Fri, Nov 10, 2023 - Mon, Nov 14, 2023       Implementation of Universal Hepatitis C Virus Screening in a Tertiary Care Cancer Center - (04/15/24)   Total HCV patients treated with direct acting antivirals since 2014: Generics of Latest DAAs Are Key to Continuing Global Expansion of HCV Therapy - Mark Mascolini (11/29/23)   Higher-Than-Expected Isolated Hep B Core Antibodies in Philadelphia Screening - Mark Mascolini (11/29/23)   100% SVR Rate in National Pediatric HCV Network for England-Wales-Ireland - Mark Mascolini (11/29/23)   Food Insecurity, Low Income Drive MASLD in US Adolescents - Mark Mascolini (11/29/23)   Fraction of Liver Injuries From Dietary Supplements Rising in US - Mark Mascolini (11/29/23)   Alcohol and Low Health Literacy Hamper Access to Curative Therapy for HCC - Mark Mascolini (11/29/23)   Re-vaccination against hepatitis B in previous non-responders following hepatitis C eradication - Mark Mascolini (11/29/23)   Metabolomic profiling to predict histologic progression of liver fibrosis in patients with HIV and HBV coinfection: 20% have fibrosis progression in 3 years One in 5 With HIV/HBV Has Fibrosis Progression in 3 Years; Culprit Metabolites Identified - Mark Mascolini (11/29/23)   HBV Vaccine Improves Survival With Liver Diseases Beyond HBV Infection - Mark Mascolini - (11/29/23)   MUSCLE FAT INFILTRATION IS ELEVATED IN PREFRAIL AND MODERATELY PHYSICALLY IMPAIRED PATIENTS - INTERIM RESULTS FROM THE PROSPECTIVE MULTI-CENTER CIRRHOSIS COHORT STUDY ACCESS-ESLD - (11/21/23)   Long term HBsAg reduction by a nasal administrative therapeutic vaccine containing HBsAg and HBcAg mixed with mucoadhesive CVP (CVP-NASVAC) in patients with chronic HBV infection: The results of 48 months follow up - (11/21/23)   Global inequities - WHO perspectives and policies for reducing hepatitis related health disparities in low and middle income countries - (11/21/23)   Early Read-Time Performance of the OraQuick® HCV Rapid Antibody Assay for the Exclusion of HCV Viremia - (11/21/23)   Successful Screening, Linkage to Care, and Treatment of Hepatitis C in a Tiny Shelter Encampment on Veterans Affairs Grounds - (11/21/23)   HCV Medication Adherence Outcomes for the Louisiana Medicaid Subscription-Based Model at Specialty Pharmacy - (11/21/23)   Update on Congress Around White House Plan to Eliminate HCV - (11/21/23)   Long-term risk of liver-related and non-liver-related death after direct-acting antiviral-mediated sustained virologic response in hepatitis C virus patients - (11/21/23)   Long-term risk of liver-related and non-liver-related death after direct-acting antiviral-mediated sustained virologic response in hepatitis C virus patients - (11/20/23)   Liver Damage & COVID Vaccines - (11/20/23)   Lean Mash Means Higher Mortality-But Less Decompensation-in US Veterans - Mark Mascolini (11/20/23)   Aldafermin Meets 48-Week Primary and Secondary Endpoints for MASH Cirrhosis - Mark Mascolini (11/20/23)   Empagliflozin (SGLT-2) Cuts Liver Fat in People With T2DM and Obese People Without T2DM - Mark Mascolini - (11/20/23)   Saroglitazar Lowers ALT and Triglycerides, Reducing Liver Stiffness in MASH - Mark Mascolini (11/20/23)   TRIPLE HORMONE RECEPTOR AGONIST RETATRUTIDE RESOLVES STEATOSIS IN >85 % OF SUBJECTS WITH MASLD AND OBESITY IN ASSOCIATION WITH IMPROVED METABOLIC HEALTH - (11/20/23)   Lubiprostone reduces fat content on MRI-PDFF in patients with MASLD: A 48-week randomized clinical trial - (11/20/23)   Topline Results from a 12-Week Phase 2a Trial (DUET) Evaluating TERN-501, a Highly Selective Thyroid Hormone Receptor (THR) β Agonist, Either as Monotherapy or in Combination with TERN-101, a Nonsteroidal Farnesoid X Receptor (FXR) Agonist, Demonstrated Significant Reductions in MR-Based Liver Fat Content and Fibroinflammation in Patients with Presumed MASH - (11/20/23)   Efruxifermin in Compensated Cirrhosis due to NASH/MASH: Results from a Randomized, Double-blind, Placebo-controlled, Phase 2b Trial (SYMMETRY) - (11/20/23)   Six-Year Follow-up of Managing Predominantly Hispanic Patients with Significant Steatosis at a Primary Care Clinic - (11/20/23)   Digital image quantification of the antifibrotic effect of semaglutide and the impact of liver fat in non-alcoholic steatohepatitis - (11/20/23)   Maximizing the Benefits of Statin Therapy for Liver Disease Prevention - Targeting Patients with unmet Statin Therapy Needs - (11/20/23)   Daily Aspirin Therapy for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Controlled Trial - (11/20/23)   Epidemiological and Clinical Characteristics of HBV and HDV Co-infected Patients Followed by the Canadian HBV Network - (11/20/23)   A 5-YEAR SNAPSHOT OF NATIONAL DELTA HEPATITIS SCREENING IN METROPOLITAN FRANCE: DELTA DESCRIBE - DATA ISSUED FROM THE FRENCH HEALTH INSURANCE - (11/20/23)   Baseline Characteristics of Hepatitis Delta Patients Enrolled Across Phase 2 and 3 Studies of Bulevirtide - (11/20/23)   Relationship Between ALT Normalization Rates and Different Virologic Response Criteria in Chronic HDV Patients Treated With Bulevirtide Monotherapy - (11/20/23)   The need for caregiver support in patients with hepatitis D virus infection: descriptive results from a real-world survey in Germany, Italy, Spain and the United States of America - (11/20/23)   Development of Antidrug Antibodies on Bulevirtide Monotherapy in Chronic Hepatitis Delta Does Not Impact Bulevirtide Efficacy, Safety, or Pharmacokinetics - (11/20/23)   Continued TDF for High HBV Load and Mild ALT Elevation Improves Fibrosis - Mark Mascolini (11/20/23)   Efficacy and safety of xalnesiran with and without an immunomodulator in virologically suppressed participants with chronic hepatitis B (CHB): Primary endpoint results from the phase 2, randomized, controlled, adaptive, open-label platform study (PIRANGA) - (11/20/23)   Long-term effectiveness and safety of tenofovir alafenamide for treatment-naïve and experienced patients with chronic hepatitis B: Results from a real-world, multicenter study - (11/20/23)   Pegylated Interferon Reduces Relapses Following Bepirovirsen Treatment in Participants With Chronic Hepatitis B Virus Infection on Nucleos(t)ide Analogues: End of Study Results From the Phase 2b B-Together Study - (11/20/23)   HDV persists in human hepatocytes undergoing cell division in human liver chimeric mice but is potently inhibited by pegylated interferon-alpha treatment - (11/19/23)   THE RISK OF LIVER FIBROSIS IS GREATEST IN AREAS OF HIGHER SOCIOECONOMIC DEPRIVATION: A RISK-FACTOR BASED POPULATION SCREENING STUDY 33% vs 10% - (11/19/23)   IDENTIFICATION OF THE ENVIRONMENTAL POLLUTANTS AND METABOLIC PATHWAYS ASSOCIATED WITH NONALCOHOLIC FATTY LIVER DISEASE SEVERITY - (11/19/23)   AN AGE-STATIN INTERPLAY IN PREVENTING THE DEVELOPMENT OF CIRRHOSIS IN A 10-YEAR COHORT OF PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) - (11/19/23)   Long-Term Safety and Efficacy of Sofosbuvir-Based Direct-Acting Antivirals in Pediatric Patients With Hepatitis C Virus - (11/17/23)   Early Menopause and Primary Ovarian Insufficiency in Women With and Without Chronic Hepatitis C: A Retrospective Observational Study of Women in the United States - (11/17/23)   Local Gilead Elimination Programs Leading to Global Action in HCV (LEGA-C): Outcome of Studies and the Impact Focusing on Activities Within the United States - (11/17/23)   LOW ANTIVIRAL TREATMENT RATE (24%) FOR PATIENTS WITH HEPATITIS C (HCV)-RELATED HEPATOCELLULAR CARCINOMA (HCC)- A REAL-WORLD NATIONWIDE U.S. STUDY - (11/17/23)   ONGOING EXPERIENCE OF IMPLEMENTING THE TORONTO PROTOCOL: AN ULTRA-SHORT COURSE GLECAPRIVER/PIBRENTASVIR WITH EZETIMIBE FOR SOLID ORGAN TRANSPLANTATION FROM HCV-INFECTED DONORS TO HCV-UNINFECTED RECIPIENTS - (11/17/23)   CHARACTERIZING LINKAGE TO HEPATITIS C VIRUS CARE DURING AND FOLLOWING PREGNANCY: IDENTIFYING MISSED OPPORTUNITIES FOR TESTING AND TREATMENT, as many as 500 HCV+ infants missed, preventable - (11/17/23)   HEALTHCARE ACCESS THROUGH FACILITATED TELEMEDICINE FOR UNDERSERVED POPULATIONS: A STEPPED WEDGE CLUSTER RANDOMIZED CONTROLLED TRIAL OF HEPATITIS C VIRUS TREATMENT AMONG PERSONS WITH OPIOID USE DISORDER - (11/17/23)   RECOMPENSATION OF CHRONIC HEPATITIS C-RELATED DECOMPENSATED CIRRHOSIS FOLLOWING DIRECT-ACTING ANTIVIRAL THERAPY: REAL-WORLD DATA FROM THE PUNJAB HCV ELIMINATION MODEL - (11/17/23)   AN OPEN-LABEL ROLLOVER STUDY FOLLOWING A RANDOMIZED TRIAL FOR CHRONIC HEPATITIS B WITH HIGH SERUM VIRAL LOAD BUT MILD ELEVATED AMINOTRANSFERASE - (11/16/23)   Peripheral Single Cell Gene Expression Changes in Response to Toll-Like Receptor 8 Agonist Treatment in Chronic Hepatitis B Patients - (11/16/23)   The Share of Total HBV Infections by Age at the Global and Regional Level, 2022 - (11/16/23)   Hepatitis Debrief at AASLD 2023 (HCV, HBV, HDV), Jennifer Price MD - (11/15/23)   Artificial Intelligence to Measure Fibrosis Change on Liver Biopsy - (11/15/23)   Artificial Intelligence-based Measurement of NASH Histology (AIM-NASH) recapitulates primary results from Phase 3 study of resmetirom for treatment of NASH/MASH with liver fibrosis - (11/15/23)   RELATIONSHIP OF NON-INVASIVE MEASURES WITH HISTOLOGICAL RESPONSE IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS AND FIBROSIS: 52-WEEK DATA FROM THE PHASE 3 MAESTRO-NASH TRIAL - (11/15/23)   Tenofovir versus entecavir in preventing HCC and death: answer from a large integrated health plan population - Mark Mascolini (11/15/23)   IMMEDIATE POSTPARTUM CESSATION OF TENOFOVIR IN HIGHLY VIREMIC PREGNANT MOTHERS WITH CHRONIC HEPATITIS B INFECTION: MATERNAL AND INFANT OUTCOMES - (11/15/23)   A PHASE 2b, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND TREATMENT REGIMENS OF VTP-300 COMBINED WITH LOW-DOSE NIVOLUMAB IN CHRONIC HEPATITIS B INFECTION - (11/15/23)   VIR-2218 and VIR-3434 with or without Pegylated Interferon Alfa-2a for the Treatment of Chronic HBV Infection: End-of-Treatment Results After 24 Weeks of Therapy (MARCH Study Part B) - (11/15/23)   Liver-related Complications in Patients with HDV Higher than in HBV Mono-Infected Patients: A Regional NYC-Based Assessment - (11/15/23)   LIVER STIFFNESS MEASUREMENT TO DETECT SEVERE FIBROSIS AND CIRRHOSIS IN PATIENTS WITH CHRONIC HEPATITIS D INFECTION - (11/15/23)   The monoclonal antibody VIR-3434 and siRNA VIR-2218 for the treatment of chronic Hepatitis D Virus: preliminary results from the Phase 2 SOLSTICE trial - (11/15/23)   Efficacy and Safety of Bulevirtide in Combination with Pegylated Interferon alfa-2a in Patients with Chronic Hepatitis Delta: Primary Endpoint Results from a Phase 2b Open-Label, Randomized, Multicenter Study MYR204 - (11/15/23)   Results From an Integrated Analysis at Week 96: Continued Treatment of Early Virologic Non-responders or Partial Responders With Bulevirtide Monotherapy for Chronic Hepatitis Delta Leads to Improvement in Virologic and Biochemical Responses - (11/15/23)   Low HEPATITIS DELTA TESTING TRENDS IN A U.S. NATIONAL COHORT (2000-2022): AN ANALYSIS OF PATIENT AND PROVIDER-LEVEL PREDICTIVE FACTORS - (11/15/23)   Occurrence of Liver-Related Events in Individuals With Hepatitis Delta Virus: A Systematic Review - (11/15/23)   The efficacy and safety of 12-week SOF/VEL regimen combined with prophylactic use of TAF for treatment-naive genotype1-6 HCV/HBV co-infection adult patients with or without compensated cirrhosis in China: a multi-center prospective, single-arm, open-label trial - (11/15/23)   A HEPATITIS C (HCV) TEST AND TREAT INITIATIVE IN RESIDENT ASSOCIATED ACADEMIC PRIMARY CARE CLINIC: UPDATES IN AN ERA OF EXPANDED SCREENING GUIDELINES - (11/15/23)   The Relationship of VADOC [prison] Inmates with Hepatitis C and the Barriers Preventing the Initiation of DAA Treatment - (11/15/23)   Evolution over two years of the annual incidence of HCV viral load detected by rapid RT PCR (Xpert HCV Viral Load Fingerstick assay) directly on site in 3 addiction centers - (11/15/23)   EXPLORING HEPATITIS C VIRUS TRANSMISSION AMONG PEOPLE WHO INJECT DRUGS AND MEN WHO HAVE SEX WITH MEN: RARE AND LIMITED RISK GROUPS IN JAPAN: prioritize MSM control measures - (11/15/23)   Hepatitis C Virus Infection and COVID-19 Inpatient Mortality: HCV cirrhosis increased COVID mortality - (11/15/23)   Under 25% With HCV and HCC Got DAAs in Nationwide US Insurance Database - Mark Mascolini (11/15/23)   Estimating Prevalence (over 4 million, up to 5.6 mill.) of Hepatitis C Virus Infection in the United States, 2017-2020 - (11/15/23)   RECOMPENSATION OF CHRONIC HEPATITIS C-RELATED DECOMPENSATED CIRRHOSIS FOLLOWING DIRECT-ACTING ANTIVIRAL THERAPY: REAL-WORLD DATA FROM THE PUNJAB HCV ELIMINATION MODEL - (11/15/23)   RESMETIROM IMPROVES THE ATHEROGENIC LIPID/LIPOPROTEIN PROFILE IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS: 52-WEEK DATA FROM THE PHASE 3 MAESTRO-NASH TRIAL - (11/14/23)   Resmetirom treatment helps restore thyroid hormone levels in patients with nonalcoholic steatohepatitis: 52-week data from the Phase 3 MAESTRO-NASH trial - (11/14/23)   Economic and social burden of MASLD [fatty liver] in the United States - (11/14/23)   Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLD's The Liver Meeting® 2023 - (11/14/23)   Bone and Renal Safety of Tenofovir Alafenamide at 8 Years in Chronic HBV Patients With Underlying Risk Factors for Use of Tenofovir Disoproxil Fumarate - (11/14/23)   Preliminary Off-Treatment Responses Following 48 Weeks of Vebicorvir, Nucleos(t)ide Reverse Transcriptase Inhibitor, and AB-729 Combination in Virologically Suppressed Patients With Hepatitis B e Antigen Negative Chronic Hepatitis B: Analysis From an Open-Label Phase 2 Study - (11/14/23)   Pegylated interferon reduces relapses following bepirovirsen treatment in participants with chronic hepatitis B virus infection on nucleos(t)ide analogs: end of study results from the Phase 2b B-Together study - (11/14/23)   Intrahepatic changes in viral and immune markers following treatment with JNJ-73763989 (JNJ-3989) and nucleos(t)ide analogs (NAs), in patients with chronic hepatitis B (CHB): INSIGHT Week 40 interim results - (11/14/23)   HBV Treatment Can Reduce Risk of Kidney Disease Among Patients With Hepatitis B, Yet Treatment in the US Reflects Inequities in Care - (11/14/23)   Impact of Long-term Treatment With Continuous Tenofovir Alafenamide or After Switching From Tenofovir Disoproxil Fumarate on Hepatocellular Carcinoma Incidence in Patients With Chronic Hepatitis B - (11/14/23)   Pharmacokinetics and Safety of VIR-2218 Monotherapy in & Adult Cirrhotic Participants with Moderate Hepatic Impairment - (11/14/23)   Predictors of treatment initiation among high-risk and grey area chronic hepatitis B patients in a real-world clinical practice setting in the United States - (11/14/23)   Initial Evaluation of Immune Complex Binding in a Phase 1 Safety and Tolerability Study of Chronic HBV Participants Given a Single Dose of VIR-3434 - (11/14/23)   Baseline nucleotide polymorphisms within HBV target site in chronic hepatitis B subjects do not impact HBsAg reductions mediated by RNA interference therapeutic Imdusiran (AB-729) - (11/14/23)   Assessment of Regional Impact on the Pharmacokinetics of VIR-2218 (BRII-835) in Participants with Chronic Hepatitis B Infection - (11/14/23)   Efficacy and Safety of siRNA JNJ-73763989, Capsid Assembly Modulator-E JNJ-56136379, and Nucleos(t)ide Analogs With Pegylated Interferon Alpha-2a Added in Immune-tolerant Patients With Chronic Hepatitis B Virus Infection: Interim Results From the Phase 2 REEF-IT Study - (11/14/23)   The Impact of Changing HBV Treatment Eligibility on Portion Eligible for Treatment by Region, 2024 - (11/14/23)   TENOFOVIR ALAFENAMIDE FUMARATE WAS EFFECTIVE AND SAFE FOR CHB PATIENTS WITH LIVER CIRRHOSIS: A REAL-WORD EVIDENCE IN CHINA - (11/14/23)   Burden of Hepatitis D Virus infection in Italy: interim analysis from a prospective multicentre nationwide study - (11/14/23)   Health Care Resource Utilization and Costs of HDV Infection vs HBV Monoinfection Across Disease States in a Hospital Records Database From Spain - (11/14/23)   HDV Superinfection Doubles Risk of HCC Versus HBV Infection Alone - Mark Mascolini (11/14/23)   National and Regional Prevalence of Hepatitis Delta Virus Among Commercially Insured Patients in the US - (11/14/23)   VIR-2218 and VIR-3434 Therapy Is Efficacious in Preclinical Models of Hepatitis Delta Virus Infection - (11/13/23)   Prevalence of Hepatitis B and D Virus Among a Nationally Representative Insured Population in the United States - (11/13/23)   UNDERSTANDING THE ANTIVIRAL EFFECTS OF PEGINTERFERON LAMBDA WITH AND WITHOUT RITONAVIR BOOSTED LONAFARNIB IN CHRONIC HEPATITIS D INFECTION - (11/13/23)   BASELINE PREDICTORS OF VIROLOGICAL AND BIOCHEMICAL RESPONSES IN HDV COMPENSATED CIRRHOTIC PATIENTS TREATED WITH BULEVERTIDE MONOTHERAPY (HEP4Di STUDY) - (11/13/23)   BULEVIRTIDE IN PATIENTS WITH NON-COMPENSATED LIVER CIRRHOSIS DUE TO HEPATITIS D - (11/13/23)   Improvement in Noninvasive Markers of Fibrosis (LSM, FIB-4, and APRI) Is Seen Over 96 Weeks of Bulevirtide Monotherapy in Chronic Hepatitis Delta Regardless of Virologic Response - (11/13/23)   Bulevirtide: Treatment for Hepatitis D and Beyond USA Status - (11/13/23)   No Detectable Resistance to Bulevirtide Monotherapy Through 96 Weeks Treatment in Patients With Chronic Hepatitis Delta - (11/13/23)   Is it useful to add peg-IFN in poor responder patients to bulevirtide 2 mg? Results from the French multicenter early access program - Mark Mascolini (11/13/23)   Poor Followup After HVC SVR: High Rate of Liver and Nonliver Problems After SVR in People With Cirrhosis - Mark Mascolini (11/13/23)   Safety, Tolerability, and Outcomes of Sofosbuvir/Velpatasvir in Treatment of Chronic Hepatitis C Virus during Pregnancy: interim results from the STORC study - (11/13/23)   Bemnifosbuvir and ruzasvir are potent HCV DAAs with favorable antiviral profiles against major HCV NS5A and NS5B RAVs supporting use in combination - (11/13/23)   Lack of pharmacokinetic drug-drug interaction between bemnifosbuvir and ruzasvir in healthy participants - (11/13/23)   Efficacy and safety of SOF/VEL treatment in recently acquired hepatitis C virus infection among people living with human immunodeficiency virus: a single-center study in Southwest China - (11/13/23)   Effectiveness and safety of sofobuvir/velpatasvir/vosilaprevir as a rescue therapy for chronic hepatitis C patients GT 3b with failed previous direct-acting antivirals treatment in Southwest China - (11/13/23)   Eliminating HepC in children; Care closer to home UK - (11/13/23)   Towards ultra-short DAA therapy to eradicate HCV infection? - (11/13/23)   EFFICACY AND SAFETY OF 8-WEEK GLECAPREVIR/PIBRENTASVIR FOR THE TREATMENT OF PATIENTS WITH ACUTE HEPATITIS C: A SINGLE-ARM RETROSPECTIVE STUDY 99% - (11/13/23)   SAFETY AND TOLERABILITY OF AN ORAL CONTRACEPTIVE CONTAINING LOW-DOSE ETHINYL ESTRADIOL COMBINED WITH GLECAPREVIR/PIBRENTASVIR TREATMENT IN HEALTHY PREMENOPAUSAL WOMEN: RESULTS OF A PHASE 1 STUDY - (11/13/23)   HCV in USA: treated, diagnosed, deaths: 39% diagnosed - (11/08/23)   Total HCV patients treated with direct acting antivirals since 2014 - (11/14/23)   Increased Risk for NAFLD, MASLD to 34% - (11/08/23)